JP2023535074A5 - - Google Patents
Info
- Publication number
- JP2023535074A5 JP2023535074A5 JP2023504636A JP2023504636A JP2023535074A5 JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5 JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- disease
- antibody
- myopathy
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026032104A JP2026102651A (ja) | 2020-07-23 | 2026-03-02 | 筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055785P | 2020-07-23 | 2020-07-23 | |
| US63/055,785 | 2020-07-23 | ||
| US202063061842P | 2020-08-06 | 2020-08-06 | |
| US63/061,842 | 2020-08-06 | ||
| US202063069078P | 2020-08-23 | 2020-08-23 | |
| US63/069,078 | 2020-08-23 | ||
| US202163143831P | 2021-01-30 | 2021-01-30 | |
| US63/143,831 | 2021-01-30 | ||
| US202163181450P | 2021-04-29 | 2021-04-29 | |
| US63/181,450 | 2021-04-29 | ||
| PCT/US2021/041003 WO2022020108A1 (en) | 2020-07-23 | 2021-07-09 | Muscle-targeting complexes and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026032104A Division JP2026102651A (ja) | 2020-07-23 | 2026-03-02 | 筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535074A JP2023535074A (ja) | 2023-08-15 |
| JP2023535074A5 true JP2023535074A5 (cg-RX-API-DMAC7.html) | 2024-07-18 |
| JP7828947B2 JP7828947B2 (ja) | 2026-03-12 |
Family
ID=79728348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504636A Active JP7828947B2 (ja) | 2020-07-23 | 2021-07-09 | 筋標的化複合体およびそれらの使用 |
| JP2026032104A Pending JP2026102651A (ja) | 2020-07-23 | 2026-03-02 | 筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026032104A Pending JP2026102651A (ja) | 2020-07-23 | 2026-03-02 | 筋標的化複合体およびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230287108A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185329A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7828947B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN121270701A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021313058A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186755A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020108A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| CN116096890A (zh) | 2020-04-02 | 2023-05-09 | 米雷楚莱股份有限公司 | 使用工程化寡核苷酸的靶向抑制 |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3222816A1 (en) * | 2021-06-21 | 2022-12-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
| JPWO2022270585A1 (cg-RX-API-DMAC7.html) | 2021-06-23 | 2022-12-29 | ||
| CA3226301A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4366774A4 (en) * | 2021-07-09 | 2025-11-19 | Dyne Therapeutics Inc | MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| WO2023168427A1 (en) * | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| US12527877B2 (en) | 2024-01-24 | 2026-01-20 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
| WO2025215092A1 (en) * | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734799B2 (en) * | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
| AU2011349443B2 (en) * | 2010-12-20 | 2015-12-24 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| UY37523A (es) | 2016-12-15 | 2018-07-31 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
| PE20210125A1 (es) | 2017-10-14 | 2021-01-19 | Abbvie Inc | Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos |
| UY38247A (es) * | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| AU2019315593B2 (en) * | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| EP3829594A4 (en) * | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| WO2020028832A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7700039B2 (ja) * | 2019-01-04 | 2025-06-30 | マレンゴ・セラピューティクス,インコーポレーテッド | 抗tcr抗体分子およびその使用 |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| MX2023000958A (es) * | 2020-07-23 | 2023-04-14 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica. |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| US20230256112A1 (en) * | 2020-07-23 | 2023-08-17 | Dyne Therapeutics, lnc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| CN116348139A (zh) * | 2020-07-23 | 2023-06-27 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
-
2021
- 2021-07-09 AU AU2021313058A patent/AU2021313058A1/en active Pending
- 2021-07-09 WO PCT/US2021/041003 patent/WO2022020108A1/en not_active Ceased
- 2021-07-09 EP EP21845571.5A patent/EP4185329A4/en active Pending
- 2021-07-09 CN CN202511290690.3A patent/CN121270701A/zh active Pending
- 2021-07-09 CN CN202180064691.XA patent/CN116194470B/zh active Active
- 2021-07-09 US US18/017,180 patent/US20230287108A1/en active Pending
- 2021-07-09 JP JP2023504636A patent/JP7828947B2/ja active Active
- 2021-07-09 CA CA3186755A patent/CA3186755A1/en active Pending
-
2026
- 2026-03-02 JP JP2026032104A patent/JP2026102651A/ja active Pending